Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.78B P/E - EPS this Y 31.70% Ern Qtrly Grth -
Income -440.22M Forward P/E -4.75 EPS next Y 44.20% 50D Avg Chg -9.00%
Sales 32.77M PEG 0.38 EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book 2.42 EPS next 5Y -19.00% 52W High Chg -46.00%
Recommedations 1.90 Quick Ratio 4.74 Shares Outstanding 303.51M 52W Low Chg 36.00%
Insider Own 0.53% ROA -33.35% Shares Float 224.41M Beta 0.63
Inst Own 87.46% ROE -65.36% Shares Shorted/Prior 60.29M/59.33M Price 7.18
Gross Margin -44.43% Profit Margin - Avg. Volume 6,016,856 Target Price 24.42
Oper. Margin -327.64% Earnings Date Oct 30 Volume 4,421,887 Change -0.14%
About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Iovance Biotherapeutics, Inc. News
12/20/24 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
12/19/24 If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick These
12/17/24 2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
12/12/24 Prediction: This Stock Will Beat the Market in 2025
12/07/24 3 Monster Stocks to Hold for the Next 10 Years
12/03/24 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63%
11/27/24 Is Iovance Biotherapeutics Stock a Millionaire Maker?
11/26/24 Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
11/23/24 Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back
11/23/24 Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds
11/22/24 2 Innovative Stocks That Could Deliver Outsize Returns
11/22/24 Iovance Biotherapeutics Inc. (IOVA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
11/12/24 Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations
11/09/24 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
11/08/24 IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
11/08/24 Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ...
11/07/24 Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates
11/07/24 Iovance Biotherapeutics: Q3 Earnings Snapshot
11/07/24 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
11/05/24 High Growth Tech Stocks to Watch in November 2024
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Rothbaum Wayne P. Director Director Sep 15 Buy 5.3 5,000,000 26,500,000 23,067,333 09/15/23
Rothbaum Wayne P. Director Director Dec 02 Buy 6.50 10,000,000 65,000,000 18,067,333 12/02/22
Vogt Frederick G Interim CEO & Genera.. Interim CEO & General Counsel Nov 28 Buy 5.98 1,000 5,980 2,000 11/28/22
MCPEAK MERRILL A Director Director Nov 28 Buy 6.18 10,000 61,800 228,633 11/28/22
Dukes Iain D. Director Director Nov 23 Buy 6.10 10,000 61,000 22,000 11/28/22
MCPEAK MERRILL A Director Director May 31 Buy 6.82 20,000 136,400 218,633 06/02/22
Maynard Ryan D Director Director May 31 Buy 6.745 7,500 50,588 7,500 06/02/22
WEISER MICHAEL Director Director May 31 Buy 6.8 10,000 68,000 112,632 06/02/22
Vogt Frederick G Interim CEO & Genera.. Interim CEO & General Counsel Jun 01 Buy 6.44 1,000 6,440 1,000 06/02/22
Rothbaum Wayne P. Director Director May 31 Buy 6.6 1,000,000 6,600,000 8,067,333 06/02/22